Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will ...